Literature DB >> 29946004

Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study.

Marianne S Muhlebach1,2, Joseph E Hatch2,3, Gisli G Einarsson4,5, Stef J McGrath4, Deirdre F Gilipin4, Gillian Lavelle6, Bojana Mirkovic6, Michelle A Murray6, Paul McNally7,8, Nathan Gotman9, Sonia Davis Thomas9,10, Matthew C Wolfgang2,11, Peter H Gilligan12,13, Noel G McElvaney6, J Stuart Elborn5,14, Richard C Boucher2, Michael M Tunney4,5.   

Abstract

Anaerobic and aerobic bacteria were quantitated in respiratory samples across three cystic fibrosis (CF) centres using extended culture methods. Subjects aged 1-69 years who were clinically stable provided sputum (n=200) or bronchoalveolar lavage (n=55). 18 anaerobic and 39 aerobic genera were cultured from 59% and 95% of samples, respectively; 16 out of 57 genera had a ≥5% prevalence across centres.Analyses of microbial communities using co-occurrence networks in sputum samples showed groupings of oral, including anaerobic, bacteria, whereas typical CF pathogens formed distinct entities. Pseudomonas was associated with worse nutrition and F508del genotype, whereas anaerobe prevalence was positively associated with pancreatic sufficiency, better nutrition and better lung function. A higher total anaerobe/total aerobe CFU ratio was associated with pancreatic sufficiency and better nutrition. Subjects grouped by factor analysis who had relative dominance of anaerobes over aerobes had milder disease compared with a Pseudomonas-dominated group with similar proportions of subjects that were homozygous for F508del.In summary, anaerobic bacteria occurred at an early age. In sputum-producing subjects anaerobic bacteria were associated with milder disease, suggesting that targeted eradication of anaerobes may not be warranted in sputum-producing CF subjects.
Copyright ©ERS 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29946004      PMCID: PMC6376871          DOI: 10.1183/13993003.00242-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  43 in total

1.  rrndb: the Ribosomal RNA Operon Copy Number Database.

Authors:  J A Klappenbach; P R Saxman; J R Cole; T M Schmidt
Journal:  Nucleic Acids Res       Date:  2001-01-01       Impact factor: 16.971

2.  Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.

Authors:  G Laszlo
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

3.  Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis.

Authors:  J Kirk Harris; Mary Ann De Groote; Scott D Sagel; Edith T Zemanick; Robert Kapsner; Churee Penvari; Heidi Kaess; Robin R Deterding; Frank J Accurso; Norman R Pace
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

4.  Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.

Authors:  Dieter Worlitzsch; Robert Tarran; Martina Ulrich; Ute Schwab; Aynur Cekici; Keith C Meyer; Peter Birrer; Gabriel Bellon; Jürgen Berger; Tilo Weiss; Konrad Botzenhart; James R Yankaskas; Scott Randell; Richard C Boucher; Gerd Döring
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

5.  Disease-specific reference equations for lung function in patients with cystic fibrosis.

Authors:  Michal Kulich; Margaret Rosenfeld; Jonathan Campbell; Richard Kronmal; Ron L Gibson; Christopher H Goss; Bonnie Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2005-06-23       Impact factor: 21.405

Review 6.  Development of oral bacterial flora in young children.

Authors:  E Könönen
Journal:  Ann Med       Date:  2000-03       Impact factor: 4.709

7.  ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis.

Authors:  Dominique Turck; Christian P Braegger; Carla Colombo; Dimitri Declercq; Alison Morton; Ruzha Pancheva; Eddy Robberecht; Martin Stern; Birgitta Strandvik; Sue Wolfe; Stephane M Schneider; Michael Wilschanski
Journal:  Clin Nutr       Date:  2016-03-15       Impact factor: 7.324

8.  Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis.

Authors:  Yan Wei Lim; Jose S Evangelista; Robert Schmieder; Barbara Bailey; Matthew Haynes; Mike Furlan; Heather Maughan; Robert Edwards; Forest Rohwer; Douglas Conrad
Journal:  J Clin Microbiol       Date:  2013-11-20       Impact factor: 5.948

9.  The Role of Short-Chain Fatty Acids, Produced by Anaerobic Bacteria, in the Cystic Fibrosis Airway.

Authors:  Bojana Mirković; Michelle A Murray; Gillian M Lavelle; Kevin Molloy; Ahmed Abdul Azim; Cedric Gunaratnam; Fiona Healy; Dubhfeasa Slattery; Paul McNally; Joe Hatch; Matthew Wolfgang; Michael M Tunney; Marianne S Muhlebach; Rosaleen Devery; Catherine M Greene; Noel G McElvaney
Journal:  Am J Respir Crit Care Med       Date:  2015-12-01       Impact factor: 21.405

10.  Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients.

Authors:  D Worlitzsch; C Rintelen; K Böhm; B Wollschläger; N Merkel; M Borneff-Lipp; G Döring
Journal:  Clin Microbiol Infect       Date:  2009-01-22       Impact factor: 8.067

View more
  27 in total

1.  Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics.

Authors:  Miquel B Ekkelenkamp; Rafael Cantón; María Díez-Aguilar; Michael M Tunney; Deirdre F Gilpin; Francesca Bernardini; Glenn E Dale; J Stuart Elborn; Jumamurat R Bayjanov; Ad Fluit
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Integrative microbiomics in bronchiectasis exacerbations.

Authors:  Micheál Mac Aogáin; Jayanth Kumar Narayana; Pei Yee Tiew; Nur A'tikah Binte Mohamed Ali; Valerie Fei Lee Yong; Tavleen Kaur Jaggi; Albert Yick Hou Lim; Holly R Keir; Alison J Dicker; Kai Xian Thng; Akina Tsang; Fransiskus Xaverius Ivan; Mau Ern Poh; Martina Oriano; Stefano Aliberti; Francesco Blasi; Teck Boon Low; Thun How Ong; Brian Oliver; Yan Hui Giam; Augustine Tee; Mariko Siyue Koh; John Arputhan Abisheganaden; Krasimira Tsaneva-Atanasova; James D Chalmers; Sanjay H Chotirmall
Journal:  Nat Med       Date:  2021-04-05       Impact factor: 53.440

3.  Effects of hyperoxia on alveolar and pulmonary vascular development in germ-free mice.

Authors:  Kalsang Dolma; Amelia E Freeman; Gabriel Rezonzew; Gregory A Payne; Xin Xu; Tamas Jilling; J Edwin Blalock; Amit Gaggar; Namasivayam Ambalavanan; Charitharth Vivek Lal
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-10-23       Impact factor: 5.464

4.  Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis.

Authors:  Laura J Sherrard; Gisli G Einarsson; Elinor Johnston; Katherine O'Neill; Leanne McIlreavey; Stephanie J McGrath; Deirdre F Gilpin; Damian G Downey; Alastair Reid; Noel G McElvaney; Richard C Boucher; Marianne S Muhlebach; J Stuart Elborn; Michael M Tunney
Journal:  J Cyst Fibros       Date:  2019-03-21       Impact factor: 5.482

5.  Cystic Fibrosis Airway Mucus Hyperconcentration Produces a Vicious Cycle of Mucin, Pathogen, and Inflammatory Interactions that Promotes Disease Persistence.

Authors:  Bethany D Batson; Bryan T Zorn; Giorgia Radicioni; Stephanie S Livengood; Tadahiro Kumagai; Hong Dang; Agathe Ceppe; Phillip W Clapp; Michael Tunney; J Stuart Elborn; Noel G McElvaney; Marianne S Muhlebach; Richard C Boucher; Michael Tiemeyer; Matthew C Wolfgang; Mehmet Kesimer
Journal:  Am J Respir Cell Mol Biol       Date:  2022-08       Impact factor: 7.748

6.  Phenotypic characteristics of incident and chronic MRSA isolates in cystic fibrosis.

Authors:  Deirdre Gilpin; Lucas R Hoffman; Agathe Ceppe; Marianne S Muhlebach
Journal:  J Cyst Fibros       Date:  2021-06-06       Impact factor: 5.482

7.  Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.

Authors:  Lauren M Castner; Madsen Zimbric; Shannon Cahalan; Corey Powell; Lindsay J Caverly
Journal:  J Cyst Fibros       Date:  2021-02-19       Impact factor: 5.482

8.  Prevotella melaninogenica, a Sentinel Species of Antibiotic Resistance in Cystic Fibrosis Respiratory Niche?

Authors:  Claudie Lamoureux; Charles-Antoine Guilloux; Elise Courteboeuf; Stéphanie Gouriou; Clémence Beauruelle; Geneviève Héry-Arnaud
Journal:  Microorganisms       Date:  2021-06-11

9.  Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations.

Authors:  Jonathan D Cogen; Anna V Faino; Frankline Onchiri; Lucas R Hoffman; Matthew P Kronman; David P Nichols; Margaret Rosenfeld; Ronald L Gibson
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 20.999

10.  Impact of Anaerobic Antibacterial Spectrum on Cystic Fibrosis Airway Microbiome Diversity and Pulmonary Function.

Authors:  Michael J Bozzella; Hollis Chaney; Iman Sami; Anastassios Koumbourlis; James E Bost; Edith T Zemanick; Robert J Freishtat; Keith A Crandall; Andrea Hahn
Journal:  Pediatr Infect Dis J       Date:  2021-11-01       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.